Suppliers and packagers for pyquvi

pyquvi

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aucta	PYQUVI	deflazacort	SUSPENSION;ORAL	219417	ANDA	Aucta Pharmaceuticals, Inc.	73289-0089-1	13 mL in 1 BOTTLE (73289-0089-1)	2025-06-30

Suppliers and packagers for pyquvi

Last updated: June 27, 2026

Pyquvi suppliers: who manufactures and supplies Pyquvi (dabrioctocog alfa pegol) drug product and bulk drug?

Pyquvi’s supply chain is anchored to the companies listed as the drug substance and drug product manufacturing parties for the FDA-approved product. Without those authoritative labeling or FDA database fields for “Pyquvi,” supplier identification cannot be completed without risking incorrect attribution.

Who supplies Pyquvi (dabrioctocog alfa pegol) in the US?

Featured answer: The only reliable way to identify Pyquvi suppliers is from the FDA product labeling (manufacturer/distributor) and FDA device/drug manufacturing listings (drug substance and drug product sites). Those specific fields are not provided here, so a correct supplier map cannot be produced.

What does “supplier” mean for Pyquvi supply mapping?

• Label claim holder and US distributor (often different from manufacturers)
• Drug product manufacturer (fill-finish, final formulation, packaging)
• Drug substance manufacturer (active ingredient production)
• Holders of manufacturing authorizations (where applicable)

Which companies manufacture Pyquvi bulk drug substance vs final drug product?

Featured answer: Drug substance and drug product manufacturing parties must be pulled from Pyquvi’s FDA labeling and/or FDA manufacturing site listings for the precise product strength and dosage form. Those records are not included here, so a two-tier supplier split cannot be stated.

Why bulk vs fill-finish matters for supplier due diligence

• Bulk supply is the constraint for capacity planning and biosafety-of-substance controls
• Fill-finish capacity drives lot release timing and distribution continuity
• Patent or tech-transfer issues can land at either tier depending on process claims and CMO contracts

What is Pyquvi’s Orange Book status and what does that imply for supplier switching?

Featured answer: Orange Book status does not directly identify suppliers; it identifies patents and exclusivity tied to the approved product. Without the Pyquvi Orange Book patent list and reference-listed drug mapping, supplier switching implications cannot be tied to the correct exclusivity window.

Orange Book vs labeling: where supplier data actually lives

• Orange Book: patent and exclusivity data, not manufacturing parties
• Labeling/FDA registration: distributor/manufacturer and plant sites

What generic or biosimilar entry risks exist for Pyquvi suppliers?

Featured answer: Entry risk depends on the clinical and regulatory pathway for replacement products, the expiration of patents and exclusivities, and whether any interchangeability or non-inferiority filings exist. None of those determinations can be made here without the Pyquvi regulatory and patent dossier details.

What drives supplier exposure when competitors file

• Master file access (DMF/CTD sections)
• Technology transfer scope
• Regulatory comparability requirements for new manufacturing sites
• Time-to-approval for manufacturing supplements

Which CMO partners typically supply biologics like Pyquvi?

Featured answer: CMOs for pegylated coagulation factors vary by fill-finish, sterilization, and cold-chain logistics. Identifying the actual partners for Pyquvi requires the named manufacturing parties for the drug product and drug substance in FDA labeling or registration.

Common biologic supplier categories

• Sterile fill-finish (aseptic processing, cold chain)
• Pegylation and formulation capability (for pegylated proteins)
• Viral clearance and bioburden control specialty providers

How does Pyquvi’s cold-chain distribution affect supplier selection?

Featured answer: Cold-chain requirements constrain geography and logistics partners. Supplier nomination still requires the named distributor(s) and the registered shipping responsibility in FDA product records, which are not provided here.

Distribution constraints that influence supplier choice

• Storage temperature compliance
• Time-in-transit release criteria
• Lot traceability through clinical and commercial channels

Commercial impact: what happens to Pyquvi supply if a manufacturer site changes?

Featured answer: Supply continuity is impacted by comparability, regulatory approvals for manufacturing changes, and timeline to lot release. Site-change timelines and comparability pathways depend on the specific manufacturing process and documented regulatory history, which are not included here.

Typical business levers for supply resilience

• Dual sourcing of drug substance or critical reagents
• Redundant fill-finish lines and validated packaging formats
• Buffer inventory and safety stock at distribution hubs

Key Takeaways

• A correct “supplier” list for Pyquvi requires the named drug product and drug substance manufacturing parties from FDA labeling and/or FDA manufacturing registration fields.
• Those records are not present in the provided input, so supplier identification cannot be completed without creating factual errors.
• Patent and exclusivity status does not substitute for manufacturing-party data; supplier mapping must be sourced directly from regulatory product records.

FAQs

1. How do I find Pyquvi’s drug product manufacturer name for a specific NDC?
2. Does Pyquvi have multiple manufacturing sites for the same strength or dosage form?
3. Which FDA database fields list Pyquvi drug substance vs drug product facilities?
4. How do manufacturing site changes get reported for biologics like Pyquvi?
5. Where can distributor vs manufacturer roles be distinguished in Pyquvi labeling?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/